The Safety and Effectiveness of Denosumab Among Chinese With Osteoporosis and Glucocorticoid Exposure – a Real World Study in Taiwan (20220054)

Study identification

• EU PAS number:
  EUPAS49104
• Study ID:
  49446
• Official title and acronym:
  The Safety and Effectiveness of Denosumab Among Chinese With Osteoporosis and Glucocorticoid Exposure – a Real World Study in Taiwan (20220054)
• DARWIN EU® study:
  No
• Study countries:
  Taiwan
• Study status:
  Finalised

Research institutions and networks

Institutions

Amgen

United States

Study timelines

Date when funding contract was signed

Planned: 28/09/2022

Actual: 28/09/2022

Study start date

Planned: 01/10/2022

Actual: 01/10/2022

Data analysis start date

Planned: 07/10/2022

Actual: 07/10/2022

Date of final study report

Planned: 31/03/2023

Actual: 24/02/2023

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Amgen

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable